Chronic Rhinosinusitis With Nasal Polyps Market Report 2026

Chronic Rhinosinusitis With Nasal Polyps Market Overview

• Chronic Rhinosinusitis With Nasal Polyps market size has reached to $4.38 billion in 2025 • Expected to grow to $6.5 billion in 2030 at a compound annual growth rate (CAGR) of 8% • Growth Driver: Growing Respiratory Disease Fuel Rise in Chronic Rhinosinusitis Market • Market Trend: Advancements In Anti-IL-5 Biologics For CRSwNP Treatment • North America was the largest region in 2025.

What Is Covered Under Chronic Rhinosinusitis With Nasal Polyps Market?

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is a persistent inflammatory condition of the sinuses and nasal passages characterized by the presence of nasal polyps. Nasal polyps are non-cancerous, swollen masses of tissue that grow in the nasal passages or sinuses due to chronic inflammation. It is detected through a combination of symptom review, clinical examination, imaging studies, allergy testing, and sometimes biopsy. The main treatment types of chronic rhinosinusitis with nasal polyps include medications and surgical methods. Medications for chronic rhinosinusitis with nasal polyps are drugs designed to reduce inflammation, manage symptoms, and shrink polyps. The routes of administration include nasal, oral, and others. and distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Chronic Rhinosinusitis With Nasal Polyps Market Growth Forecast?

The chronic rhinosinusitis with nasal polyps market size is expected to see strong growth in the next few years. It will grow to $6.5 billion in 2030 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to increasing approvals of monoclonal antibody therapies, rising investment in ENT biologics research, expansion of outpatient sinus surgery procedures, growing focus on recurrence prevention, increasing patient preference for non-surgical options. Major trends in the forecast period include increasing adoption of biologic therapies for crswnp, rising use of minimally invasive surgical techniques, growing focus on long-term inflammation control, expansion of personalized treatment pathways, enhanced integration of diagnostic imaging and biomarkers.

Global Chronic Rhinosinusitis With Nasal Polyps Market Segmentation

1) By Treatment: Medications, Surgical Methods 2) By Route Of Administration: Nasal, Oral, Other Routes Of Administrations 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Medications: Corticosteroids (Nasal Sprays, Oral Steroids), Biologics (Monoclonal Antibodies Like Dupilumab) 2) By Surgical Methods: Endoscopic Sinus Surgery (ESS), Polypectomy (Polyps Removal), Balloon Sinuplasty

What Is The Driver Of The Chronic Rhinosinusitis With Nasal Polyps Market?

The increasing prevalence of respiratory diseases is expected to propel the growth of chronic rhinosinusitis with the nasal polyps market going forward. Respiratory diseases encompass a broad range of conditions that affect the respiratory system, including the lungs and airways. A complex interplay of factors, including air pollution, smoking, climate change, infections, occupational exposures, and allergies, drives the rising cases of respiratory diseases. With more people experiencing conditions such as asthma and chronic obstructive pulmonary disease (COPD), the incidence of associated conditions such as CRSwNP also rises, resulting in greater demand for diagnostic tools, treatments, and surgical interventions. For instance, in December 2023, according to the National Center for Biotechnology Information, a US-based government agency, global COPD prevalence is projected to near 600 million cases worldwide by 2050. Therefore, the increasing prevalence of respiratory tract infections will drive the growth of the chronic rhinosinusitis with nasal polyps industry.

Key Players In The Global Chronic Rhinosinusitis With Nasal Polyps Market

Major companies operating in the chronic rhinosinusitis with nasal polyps market are Pfizer Inc., Roche Holding AG, Merck & Co Inc, Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Medtronic plc, Boehringer Ingelheim International GmbH, Amgen Inc, Teva Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc, Daiichi Sankyo Company Limited, Olympus Corporation, Eisai Co Ltd, Smith & Nephew PLC, Genentech USA Inc, Mallinckrodt Pharmaceuticals, Lyra Therapeutics Inc, Sunovion Pharmaceuticals, Acclarent Inc., Optinose US Inc, SinuSys Corporation, Biohaven Pharmaceuticals

Global Chronic Rhinosinusitis With Nasal Polyps Market Trends and Insights

Major companies operating in the chronic rhinosinusitis with nasal polyps' market are focusing on alternative therapies, such as anti-IL-5 biologics, to improve patient outcomes and gain a competitive advantage. Anti-IL-5 biologics offer targeted therapy that reduces eosinophilic inflammation in diseases like severe asthma and eosinophilic disorders, improving symptom control and quality of life for patients. For instance, in March 2024, Optinose, a US-based pharmaceutical company that focuses on developing and commercializing innovative products, received U.S. Food and Drug Administration (FDA) approval for its XHANCE, a prescription nasal spray indicated for the treatment of chronic rhinosinusitis (CRS) in adults, specifically for both chronic rhinosinusitis with nasal polyps (CRSwNP) and chronic rhinosinusitis without nasal polyps (CRSsNP). It contains fluticasone propionate, a corticosteroid that reduces inflammation in the nasal passages. Key features is the unique Exhalation Delivery System (EDS), which allows patients to blow into the device while administering the spray, enhancing medication delivery deep into the nasal passages and effectively targeting areas where nasal polyps form and sinuses drain.

What Are Latest Mergers And Acquisitions In The Chronic Rhinosinusitis With Nasal Polyps Market?

In May 2025, Paratek Pharmaceuticals, a US-based biopharmaceutical company specializing in antibacterial and anti-infective therapies, acquired Optinose Inc. for an undisclosed amount. With this acquisition, Paratek aims to expand its specialty therapeutics portfolio, strengthen its commercial capabilities, and broaden its presence in respiratory and ENT-focused treatment segments. Optinose Inc. is a US-based specialty pharmaceutical company, that offers chronic rhinosinusitis with nasal polyps.

Regional Outlook

North America was the largest region in the chronic rhinosinusitis with nasal polyps market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Chronic Rhinosinusitis With Nasal Polyps Market?

The chronic rhinosinusitis with nasal polyps market consists of revenues earned by entities by providing services such as medical consultations, diagnostic procedures, pharmacological treatments, and surgical interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic rhinosinusitis with nasal polyps market also includes sales of nasal corticosteroid sprays, antihistamines, saline nasal sprays, and devices for nasal irrigation, as well as surgical instruments and equipment used in procedures like polypectomy and functional endoscopic sinus surgery. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Chronic Rhinosinusitis With Nasal Polyps Market Report 2026?

The chronic rhinosinusitis with nasal polyps market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the chronic rhinosinusitis with nasal polyps industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.